肿瘤浸润性淋巴细胞与不同分子类型乳腺癌预后关系的研究进展
Research Progress on the Relationship between Tumor Infiltrating Lymphocytes and Prognosis of Different Molecular Types of Breast Cancer
DOI: 10.12677/acm.2024.143903, PDF,   
作者: 侯 俊, 梁婷婷, 刘晶怡, 任俊丽, 王开元, 潘澄澄：甘肃中医药大学第一临床医学院，甘肃 兰州；马秀芬*：甘肃省妇幼保健院乳腺科，甘肃 兰州
关键词: 乳腺癌；肿瘤浸润性淋巴细胞；肿瘤微环境；新辅助化疗；Breast Cancer； Tumor Infiltrating Lymphocytes； Tumor Microenvironment； Neoadjuvant Chemotherapy
摘要: 肿瘤浸润淋巴细胞(tumor infiltrating lymphocytes, TILs)是肿瘤微环境的重要组分，既往研究表明肿瘤浸润性淋巴细胞与结肠癌及肺癌等多种肿瘤的预后有一定的关系。其对乳腺癌的预后及其相关性结论并不完全一致。乳腺癌是由不同分子亚型组成的疾病，TILs在三阴性及HRE2阳性乳腺癌的相关性研究较多，在Luminal型乳腺癌中研究较少。本综述阐述TILs对不同分子类型乳腺癌预后指示效应的相关研究进展。
Abstract: Tumor infiltrating lymphocytes (TILs) are an important component of the tumor microenvironment, and previous studies have shown a certain relationship between tumor infiltrating lymphocytes and the prognosis of various tumors such as colon cancer and lung cancer. The prognosis of breast cancer and its correlation conclusions are not completely consistent. Breast cancer is a disease composed of different molecular subtypes. There are more studies on the correlation of TILs in triple negative and HRE2 positive breast cancer, but less in Luminal breast cancer. This review reviews the research progress of the prognostic indicator effect of TILs on different molecular types of breast cancer.
文章引用：侯俊, 梁婷婷, 刘晶怡, 任俊丽, 王开元, 潘澄澄, 马秀芬. 肿瘤浸润性淋巴细胞与不同分子类型乳腺癌预后关系的研究进展[J]. 临床医学进展, 2024, 14(3): 1750-1755. https://doi.org/10.12677/acm.2024.143903

参考文献

[1] Vitale, I., Manic, G., Coussens, L.M., et al. (2019) Macrophages and Metabolism in the Tumor Microenvironment. Cell Metabolism, 30, 36-50. [Google Scholar] [CrossRef] [PubMed]
[2] Jin, M.Z. and Jin, W.L. (2020) The Updated Landscape of Tumor Microenvironment and Drug Repurposing. Signal Transduction and Targeted Therapy, 5, Article No. 166. [Google Scholar] [CrossRef] [PubMed]
[3] So, J.Y., Ohm, J., Lipkowitz, S. and Yang, L. (2022) Triple Negative Breast Cancer (TNBC): Non-Genetic Tumor Heterogeneity and Immune Microenvironment: Emerging Treatment Options. Pharmacology & Therapeutics, 237, Article ID: 108253. [Google Scholar] [CrossRef] [PubMed]
[4] Underwood, J.C. (1974) Lymphoreticular Infiltration in Human Tumours: Prognostic and Biological Implications: A Review. British Journal of Cancer, 30, 538-548. [Google Scholar] [CrossRef] [PubMed]
[5] Salgado, R., Denkert, C., Demaria, S., et al. (2015) The Evaluation of Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer: Recommendations by an International TILs Working Group 2014. Annals of Oncology, 26, 259-271. [Google Scholar] [CrossRef] [PubMed]
[6] Denkert, C., Von Minckwitz, G., Darb-Esfahani, S., et al. (2018) Tumour-Infiltrating Lymphocytes and Prognosis in Different Subtypes of Breast Cancer: A Pooled Analysis of 3771 Patients Treated with Neoadjuvant Therapy. The Lancet Oncology, 19, 40-50. [Google Scholar] [CrossRef] 
[7] Broglio, K.R., Quintana, M., Foster, M., et al. (2016) Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer with Long-Term Outcomes: A Meta-Analysis. JAMA Oncology, 2, 751-760. [Google Scholar] [CrossRef] [PubMed]
[8] Pruneri, G., Lazzeroni, M., Bagnardi, V., et al. (2017) The Prevalence and Clinical Relevance of Tumor-Infiltrating Lymphocytes (TILs) in Ductal Carcinoma in Situ of the Breast. Annals of Oncology, 28, 321-328. [Google Scholar] [CrossRef] [PubMed]
[9] Pelekanou, V., Carvajal-Hausdorf, D.E., Altan, M., et al. (2017) Effect of Neoadjuvant Chemotherapy on Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Breast Cancer and Its Clinical Significance. Breast Cancer Research, 19, Article No. 91. [Google Scholar] [CrossRef] [PubMed]
[10] Hamy, A.S., Bonsang-Kitzis, H., De Croze, D., et al. (2019) Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Clinical Cancer Research, 25, 6731-6741. [Google Scholar] [CrossRef] 
[11] Stanton, S.E., Adams, S. and Disis, M.L. (2016) Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes: A Systematic Review. JAMA Oncology, 2, 1354-1360. [Google Scholar] [CrossRef] [PubMed]
[12] Li, S., Zhang, Y., Zhang, P., et al. (2022) Predictive and Prognostic Values of Tumor Infiltrating Lymphocytes in Breast Cancers Treated with Neoadjuvant Chemotherapy: A Meta-Analysis. Breast, 66, 97-109. [Google Scholar] [CrossRef] [PubMed]
[13] Gao, G., Wang, Z., Qu, X., et al. (2020) Prognostic Value of Tumor-Infiltrating Lymphocytes in Patients with Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis. BMC Cancer, 20, Article No. 179. [Google Scholar] [CrossRef] [PubMed]
[14] Loi, S., Drubay, D., Adams, S., et al. (2019) Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. Journal of Clinical Oncology, 37, 559-569. [Google Scholar] [CrossRef] 
[15] Mangia, A., Saponaro, C., Vagheggini, A., et al. (2019) Should Tumor Infiltrating Lymphocytes, Androgen Receptor, and FOXA1 Expression Predict the Clinical Outcome in Triple Negative Breast Cancer Patients? Cancers, 11, Article 1393. [Google Scholar] [CrossRef] [PubMed]
[16] 黄婉莹, 杨向红. 三阴性乳腺癌中PD-1、PD-L1的表达与肿瘤浸润性淋巴细胞及临床病理指标的相关性[J]. 现代肿瘤医学, 2022, 30(12): 2181-2185.
[17] 范姣. 雄激素受体与肿瘤浸润性淋巴细胞对三阴性乳腺癌预后影响的相关性分析[D]: [硕士学位论文]. 大连: 大连医科大学, 2021.
[18] Park, J.H., Jonas, S.F., Bataillon, G., et al. (2019) Prognostic Value of Tumor-Infiltrating Lymphocytes in Patients with Early-Stage Triple-Negative Breast Cancers (TNBC) Who Did Not Receive Adjuvant Chemotherapy. Annals of Oncology, 30, 1941-1949. [Google Scholar] [CrossRef] [PubMed]
[19] Kumar, A., Watkins, R. and Vilgelm, A.E. (2021) Cell Therapy with TILs: Training and Taming T Cells to Fight Cancer. Frontiers in Immunology, 12, Article 690499. [Google Scholar] [CrossRef] [PubMed]
[20] Lee, H., Lee, M., Seo, J.H., et al. (2020) Changes in Tumor-Infiltrating Lymphocytes after Neoadjuvant Chemotherapy and Clinical Significance in Triple Negative Breast Cancer. Anticancer Research, 40, 1883-1890. [Google Scholar] [CrossRef] [PubMed]
[21] Luen, S.J., Salgado, R., Dieci, M.V., et al. (2019) Prognostic Implications of Residual Disease Tumor-Infiltrating Lymphocytes and Residual Cancer Burden in Triple-Negative Breast Cancer Patients after Neoadjuvant Chemotherapy. Annals of Oncology, 30, 236-242. [Google Scholar] [CrossRef] [PubMed]
[22] Kochi, M., Iwamoto, T., Niikura, N., et al. (2017) Tumour-Infiltrating Lymphocytes (TILs)-Related Genomic Signature Predicts Chemotherapy Response in Breast Cancer. Breast Cancer Research and Treatment, 167, 39-47. [Google Scholar] [CrossRef] [PubMed]
[23] Loi, S., Sirtaine, N., Piette, F., et al. (2013) Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin with Doxorubicin-Based Chemotherapy: BIG 02-98. Journal of Clinical Oncology, 31, 860-867. [Google Scholar] [CrossRef] 
[24] Loi, S., Michiels, S., Salgado, R., et al. (2014) Tumor Infiltrating Lymphocytes Are Prognostic in Triple Negative Breast Cancer and Predictive for Trastuzumab Benefit in Early Breast Cancer: Results from the FinHER Trial. Annals of Oncology, 25, 1544-1550. [Google Scholar] [CrossRef] [PubMed]
[25] Ingold Heppner, B., Untch, M., Denkert, C., et al. (2016) Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer. Clinical Cancer Research, 22, 5747-5754. [Google Scholar] [CrossRef] 
[26] Salgado, R., Denkert, C., Campbell, C., et al. (2015) Tumor-Infiltrating Lymphocytes and Associations with Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated with Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial. JAMA Oncology, 1, 448-455. [Google Scholar] [CrossRef] [PubMed]
[27] Liu, S., Mou, E., Zeng, S., et al. (2020) Therapeutic Effect of Trastuzumab in Neoadjuvant-Treated HER2-Positive Breast Cancer with Low Infiltrating Level of Tumor-Infiltrating Lymphocytes. Cancer Management and Research, 12, 3145-3153. [Google Scholar] [CrossRef] 
[28] Schmid, P., Rugo, H.S., Adams, S., et al. (2020) Atezolizumab plus Nab-Paclitaxel as First-Line Treatment for Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer (IMpassion130): Updated Efficacy Results from a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. The Lancet Oncology, 21, 44-59. [Google Scholar] [CrossRef] 
[29] García-Torralba, E., Pérez Ramos, M., Ivars Rubio, A., et al. (2023) Clinical Meaning of Stromal Tumor Infiltrating Lymphocytes (STIL) in Early Luminal B Breast Cancer. Cancers, 15, Article 2846. [Google Scholar] [CrossRef] [PubMed]
[30] Makhlouf, S., Wahab, N., Toss, M., et al. (2023) Evaluation of Tumour Infiltrating Lymphocytes in Luminal Breast Cancer Using Artificial Intelligence. British Journal of Cancer, 129, 1747-1758. [Google Scholar] [CrossRef] [PubMed]
[31] Cortazar, P., Zhang, L., Untch, M., et al. (2014) Pathological Complete Response and Long-Term Clinical Benefit in Breast Cancer: The CTNeoBC Pooled Analysis. The Lancet, 384, 164-172. [Google Scholar] [CrossRef] 
[32] Ingold Heppner, B., Untch, M., Denkert, C., et al. (2016) Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer. Clinical Cancer Research, 22, 5747-5754. [Google Scholar] [CrossRef] 
[33] Adams, S., Gray, R.J., Demaria, S., et al. (2014) Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers from Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199. Journal of Clinical Oncology, 32, 2959-2966. [Google Scholar] [CrossRef] 

为你推荐